Brief: Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral Ketamine Analog, Ketamir-2, Paving Way For IND Submission Later This Year
10/06/2024 13:56
June 10 (Reuters) - Mira Pharmaceuticals Inc MIRA.O :
* MIRA PHARMACEUTICALS ANNOUNCES POSITIVE PRECLINICAL STUDY
RESULTS FOR ITS NOVEL ORAL KETAMINE ANALOG, KETAMIR-2, PAVING
WAY FOR IND SUBMISSION LATER THIS YEAR
Source text for Eikon: ID:nPn93lLrBa
Further company coverage: MIRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing